Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGarcía Fortes, María
dc.contributor.authorHernandez-Boluda, Juan Carlos
dc.contributor.authorAlvarez-Larran, Alberto
dc.contributor.authorRaya, José M.
dc.contributor.authorAngona, Anna
dc.contributor.authorEstrada, Natalia
dc.contributor.authorFox, Maria Laura
dc.date.accessioned2022-09-06T12:05:49Z
dc.date.available2022-09-06T12:05:49Z
dc.date.issued2022-05
dc.identifier.citationGarcía-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, et al. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers. 2022 May;14(9):2331.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/8035
dc.descriptionComorbidities; Myelofibrosis; Survival
dc.description.abstractThe comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, p < 0.001), smoking (HR = 5.08, p < 0.001), dyslipidemia (HR = 4.65, p < 0.001) and hepatitis C virus (HCV) (HR = 4.26, p = 0.015) were most adversely associated with OS. Diabetes (HR = 3.01, p < 0.001), pulmonary disease (HR = 3.13, p < 0.001) and renal dysfunction (HR = 1.82, p = 0.037) were also associated with an increased risk of death. Multivariate analysis showed that pulmonary disease (HR = 2.69, p = 0.001), smoking (HR = 3.34, p < 0.001), renal dysfunction (HR = 2.08, p = 0.043) and HCV (HR = 11.49, p = 0.001) had a negative impact on OS. When ruxolitinib exposure was included in the model, the effect of each comorbidity on survival was modified. Therefore, individual comorbidities should be taken into account in determining the survival prognosis for patients with MF.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;14(9)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectComorbiditat
dc.subjectMielofibrosi - Prognosi
dc.subjectAnàlisi de supervivència (Biometria)
dc.subject.meshPrimary Myelofibrosis
dc.subject.meshComorbidity
dc.subject.meshSurvival Analysis
dc.titleImpact of Individual Comorbidities on Survival of Patients with Myelofibrosis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers14092331
dc.subject.decsmielofibrosis primaria
dc.subject.decscomorbilidad
dc.subject.decsanálisis de supervivencia
dc.relation.publishversionhttps://doi.org/10.3390/cancers14092331
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[García-Fortes M] Hematology Department, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain. Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain. [Hernández-Boluda JC] Hematology Department, Hospital Clínico, INCLIVA, 46010 Valencia, Spain. [Álvarez-Larrán A] Hematology Department, Hospital Clínic, 08036 Barcelona, Spain. [Raya JM] Hematology Department, Hospital Universitario de Canarias, 38320 Santa Cruz de Tenerife, Spain. [Angona A] Hematology Department, Hospital del Mar, 08003 Barcelona, Spain. [Estrada N] Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain. [Fox L] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35565461
dc.identifier.wos000795385800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record